Dual platelet antiaggregation therapy after myocardial revascularization surgery

Area of Science:

• Cardiovascular Surgery
• Interventional Cardiology
• Pharmacology

Background:

• Coronary artery bypass graft (CABG) is a standard treatment for coronary artery disease (CAD).
• Venous graft occlusion remains a significant challenge, impacting long-term prognosis.
• Current anti-platelet strategies, primarily aspirin, have limitations.

Purpose of the Study:

• To evaluate the efficacy and safety of dual anti-platelet therapy (DAPT) in patients undergoing CABG.
• To address the existing clinical practice and guideline discrepancies regarding DAPT in CABG patients.

Main Methods:

• Review of subgroup analyses from anti-platelet therapy studies in CABG patients.
• Analysis of existing randomized controlled trials (RCTs) concerning DAPT in this population.
• Examination of current European and American cardiology society guidelines.

Main Results:

• Subgroup analyses suggest reduced mortality and cardiovascular events with DAPT post-CABG.
• Evidence from dedicated RCTs specifically for DAPT in CABG is currently insufficient.
• Discrepancies exist in guidelines from major cardiology societies regarding DAPT indication.

Conclusions:

• DAPT may offer benefits for CABG patients, but robust evidence is limited.
• Further high-quality randomized trials are essential to establish definitive recommendations for DAPT in CABG.
• Clarification of DAPT's role is needed to resolve clinical practice uncertainties and guideline conflicts.